Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Superconductor Corporation (AMSC) vs Eli Lilly And Co (LLY) Price & Performance

American Superconductor CorporationTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

American Superconductor Corporation vs Eli Lilly And Co — how do they compare? American Superconductor Corporation trades at $32.58 (market cap $1.56B), while Eli Lilly And Co trades at $1,219.37 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 692.3× American Superconductor Corporation's market cap, and Eli Lilly And Co pays a 0.57% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.

AMSCLLY
Market Cap
$1.56B$1.08T
Sector
TechnologyHealth
52-Week High
$66.68$1.24K
52-Week Low
$25.95$639.43
Enterprise Value
$1.42B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Superconductor Corporation

AMSC trades at $33.19, up 7.1% today, showing strong momentum despite a bearish technical signal. The company reported record Q1 2026 revenue of $94.1 million, up 30% year-over-year, but missed earnings estimates due to margin pressure. Analyst consensus leans bullish with 53% buy ratings, while technical indicators show resistance at $34 and support at $30.

Outlook remains mixed with strong revenue growth and record backlog providing visibility, but margin compression and aggressive valuation pose risks. The stock offers growth potential in energy infrastructure markets, though investors should monitor execution on profitability targets amid increasing competition.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Superconductor Corporation

AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.

Read more on AMSC

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY